American Journal of Kidney Diseases
Volume 50, Issue 2 , Pages 239-247 , August 2007

Relationship of Uric Acid With Progression of Kidney Disease

  • Michel Chonchol, MD

      Affiliations

    • Division of Renal Diseases and Hypertension, University of Colorado Health Sciences Center, Denver, CO
    • Corresponding Author InformationAddress correspondence to Michel Chonchol, MD, Division of Renal Diseases and Hypertension, University of Colorado Health Sciences Center, Box C-281, Denver, CO 80262.
    • ,
  • Michael G. Shlipak, MD, MPH

      Affiliations

    • General Internal Medicine Section, University of California San Francisco Veterans Affairs Medical Center, San Francisco, CA
    • ,
  • Ronit Katz, PhD

      Affiliations

    • Collaborative Health Studies Coordinating Center, University of Washington, Seattle, WA
    • ,
  • Mark J. Sarnak, MD, MS

      Affiliations

    • Department of Medicine, Tufts-New England Medical Center, Boston, MA
    • ,
  • Anne B. Newman, MD, MPH

      Affiliations

    • Department of Epidemiology, University of Pittsburgh School of Medicine, Pittsburgh, PA
    • ,
  • David S. Siscovick, MD, MPH

      Affiliations

    • Department of Medicine, University of Washington Cardiovascular Health Research Unit, Seattle, WA
    • Department of Epidemiology, University of Washington Cardiovascular Health Research Unit, Seattle, WA
    • ,
  • Bryan Kestenbaum, MD, MS

      Affiliations

    • Division of Nephrology, University of Washington Harborview Medical Center, Seattle, WA
    • ,
  • Jan Kirk Carney, MD, MPH

      Affiliations

    • Department of Medicine, University of Vermont, Colchester, VT
    • ,
  • Linda F. Fried, MD, MPH

      Affiliations

    • Veterans Affairs Pittsburgh Healthcare System, University of Pittsburgh School of Medicine, Pittsburgh, PA.

Received 18 January 2007 ,Accepted 16 May 2007.

References 

  1. Jossa F, Farinaro E, Panico S, et al. Serum uric acid and hypertension: The Olivetti Heart Study. J Hum Hypertens. 1994;8:677–681
  2. Fang J, Alderman MH. Serum uric acid and cardiovascular mortality: The NHANES I epidemiologic follow-up study, 1971-1992 (National Health and Nutrition Examination Survey). JAMA. 2000;283:2404–2410
  3. Siu YP, Leung KT, Tong MK, Kwan TH. Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid level. Am J Kidney Dis. 2006;47:51–59
  4. Syrjanen J, Mustonen J, Pasternack A. Hypertriglyceridaemia and hyperuricaemia are risk factors for progression of IgA nephropathy. Nephrol Dial Transplant. 2000;15:34–42
  5. Bo S, Cavallo-Perin P, Gentile L, Repetti E, Pagano G. Hypouricemia and hyperuricemia in type 2 diabetes: Two different phenotypes. Eur J Clin Invest. 2001;31:318–321
  6. Iseki K, Oshiro S, Tozawa M, Iseki C, Ikemiya Y, Takishita S. Significance of hyperuricemia on the early detection of renal failure in a cohort of screened subjects. Hypertens Res. 2001;24:691–697
  7. Iseki K, Ikemiya Y, Inoue T, Iseki C, Kinjo K, Takishita S. Significance of hyperuricemia as a risk factor for developing ESRD in a screened cohort. Am J Kidney Dis. 2004;44:642–650
  8. Fessel WJ. Renal outcomes of gout and hyperuricemia. Am J Med. 1979;67:74–82
  9. Yu TF, Berger L. Impaired renal function gout: Its association with hypertensive vascular disease and intrinsic renal disease. Am J Med. 1982;72:95–100
  10. Johnson RJ, Segal MS, Srinivas T, et al. Essential hypertension, progressive renal disease, and uric acid: A pathogenetic link?. J Am Soc Nephrol. 2005;16:1909–1919
  11. Kanellis J, Feig DI, Johnson RJ. Does asymptomatic hyperuricaemia contribute to the development of renal and cardiovascular disease? (An old controversy renewed). Nephrology (Carlton). 2004;9:394–399
  12. Fried LP, Borhani NO, Enright P, et al. The Cardiovascular Health Study: Design and rationale. Ann Epidemiol. 1991;1:263–276
  13. Tell GS, Fried LP, Hermanson B, Manolio TA, Newman AB, Borhani NO. Recruitment of adults 65 years and older as participants in the Cardiovascular Health Study. Ann Epidemiol. 1993;3:358–366
  14. Levey AS, Coresh J, Balk E, et al. National Kidney Foundation: National Kidney Foundation practice guidelines for chronic kidney disease: Evaluation, classification, and stratification. Ann Intern Med. 2003;139:137–147
  15. Fried L, Solomon C, Shlipak M, et al. Inflammatory and prothrombotic markers and the progression of renal disease in elderly individuals. J Am Soc Nephrol. 2004;15:3184–3191
  16. Klein R, Klein BEK, Moss SE, Cruickshanks KJ, Brazy PC. The 10-year incidence of renal insufficiency in people with type 1 diabetes. Diabetes Care. 1999;22:743–751
  17. Psaty BM, Lee M, Savage PJ, Rutan GH, German PS, Lyles M. Assessing the use of medications in the elderly: Method and initial results in the Cardiovascular Health Study. J Clin Epidemiol. 1992;45:683–692
  18. Kuller L, Borhani N, Furberg C, et al. Prevalence of subclinical atherosclerosis and cardiovascular disease and association with risk factors in the Cardiovascular Health Study. Am J Epidemiol. 1994;139:1164–1179
  19. O’Leary DH, Polak JF, Wolfson SK, et al. CHS Collaborative Research Group Use of sonography to evaluate carotid atherosclerosis in the elderly (The Cardiovascular Health Study). Stroke. 1991;22:1155–1163
  20. Cushman M, Cornell ES, Howard PR, Bovill EG, Tracy RP. Laboratory methods and quality assurance in the Cardiovascular Health Study. Clin Chem. 1995;41:264–270
  21. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma without the use of the preparative ultracentrifuge. Clin Chem. 1972;18:499–501
  22. Macy EM, Hayes TE, Tracy RP. Variability in the measurement of C-reactive protein in healthy subjects: Implications for reference intervals and epidemiological applications. Clin Chem. 1997;43:52–58
  23. Shlipak MG, Fried LF, Cushman M, et al. Cardiovascular mortality risk in chronic kidney disease—A comparison of traditional and novel risk factors. JAMA. 2005;293:1737–1745
  24. Vaziri ND, Freel RW, Hatch M. Effect of chronic experimental renal insufficiency on urate metabolism. J Am Soc Nephrol. 1995;6:1313–1317
  25. Johnson RJ, Feig DI, Kang DH, Herrera-Acosta J. Resurrection of uric acid as a causal risk factor for essential hypertension. Hypertension. 2005;45:18–20
  26. Nakagawa T, Kang DH, Feig D, et al. Unearthing uric acid: An ancient factor with recently found significance in renal and cardiovascular disease. Kidney Int. 2006;26:1722–1725
  27. Cannon PJ, Stason WB, Demartini FE, Sommers SC, Laragh JH. Hyperuricemia in primary and renal hypertension. N Engl J Med. 1996;275:457–464
  28. Kinsey D, Walther R, Sise HS, Whitelaw G, Smithwick R. Incidence of hyperuricemia in 400 hypertensive subjects. Circulation. 1961;24:972–973
  29. Klein R, Klein BE, Cornoni JC, Maready J, Cassel JC, Tyroler HA. Serum uric acid (Its relationship to coronary heart disease risk factors and cardiovascular disease, Evans County, Georgia). Arch Intern Med. 1973;132:401–410
  30. Feig DI, Mazzali M, Kang DH, et al. Serum uric acid: A risk factor and a target for treatment?. J Am Soc Nephrol. 2006;17(suppl 2):S69–S73
  31. Nakagawa T, Tuttle KR, Short RA, Johnson RJ. Fructose-induced hyperuricemia as a causal mechanism for the epidemic of the metabolic syndrome. Nat Clin Pract Nephrol. 2005;1:80–86
  32. Masuo K, Kawaguchi H, Mikami H, Ogihara T, Tuck ML. Serum uric acid and plasma norepinephrine concentrations predict subsequent weight gain and blood pressure elevation. Hypertension. 2003;42:474–480
  33. Yamagata K, Ishida K, Sairenchi T, et al. Risk factors for chronic kidney disease in a community-based population: A 10-year follow-up study. Kidney Int. 2007;71:159–166
  34. Sarafidis PA, Khosla N, Bakris GL. Antihypertensive therapy in the presence of proteinuria. Am J Kidney Dis. 2007;49:12–26

 Originally published online as doi:10.1053/j.ajkd.2007.05.013 on June 28, 2007.

 Because an author of this manuscript is an editor for AJKD, the peer-review and decision-making processes were handled entirely by an outside editor, Michel Jadoul, MD, Cliniques Universitaires Saint Luc, who served as acting Editor-in-Chief. Details of the journal’s procedures for potential editor conflicts are given in the Editorial Policies section of the AJKD Website.

PII: S0272-6386(07)00832-3

doi: 10.1053/j.ajkd.2007.05.013

American Journal of Kidney Diseases
Volume 50, Issue 2 , Pages 239-247 , August 2007

Article Tools

* Image Usage & Resolution